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Abstract
OBJECTIVE: Sepsis is life-threatening organ dysfunction due to dysregulated host 
responses to infection. Current knowledge of human B cells alterations in sepsis is sparse. 
We tested the hypothesis that B cell loss in sepsis involves distinct sub-populations of B cells
and investigated mechanisms of B cell depletion.
DESIGN: Prospective cohort study
SETTING: Critical care units
PATIENTS: Adult sepsis patients without any documented immune comorbidity.
INTERVENTIONS: None
MEASUREMENTS and MAIN RESULTS: B cell subsets were quantified by flow cytometry;
annexin V status identified apoptotic cells and phosphorylation of intracellular kinases 
identified activation status of B cell subsets. B cell-specific survival ligand concentrations
were measured. Gene expression in purified B cells was measured by microarray. 
Differences in messenger RNA abundance between sepsis and healthy controls were 
compared.
Lymphopenia present in 74.2% of patients on admission day, was associated with lower
absolute B cell counts (median (IQR) 0.133 (0.093 – 0.277) 109cells/L) and selective 
depletion of memory B cells despite normal B cell survival ligand concentrations. Greater 
apoptotic depletion of class-switched and IgM memory cells was associated with 
phosphorylation of extracellular signal-regulated kinases, implying externally driven 
lymphocyte stress and activation-associated cell death. This inference is supported by gene 
expression profiles highlighting mitochondrial dysfunction and cell death pathways, with 
enriched intrinsic and extrinsic pathway apoptosis genes. 
CONCLUSIONS: Depletion of the memory B cell compartment contributes to the 
immunosuppression induced by sepsis. Therapies targeted at reversing this immune memory 
depletion warrant further investigation. 
Key words: Sepsis, B cells, Apoptosis, Immunosuppression, Immune memory
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INTRODUCTION
Sepsis is life-threatening organ dysfunction caused by dysregulated host responses
to infection(1). These dysregulated immune responses consist of concomitant pro-
inflammatory and anti-inflammatory components involving innate and adaptive immune 
systems(2-4). Sepsis-related immunosuppression describes a plethora of abnormalities that 
also affect both innate and adaptive immunity(2-4). Such immunoparesis predisposes septic 
patients to renewed bouts of infection (bacterial or fungal) and reactivation of dormant 
viruses(2, 4, 5). Immune abnormalities potentially persist in survivors well beyond their 
hospital discharge(6), and likely contribute to infection-related readmissions(7-11), worsening 
co-morbidities and worse long-term outcomes(12).
Both loss and decreased functionality of lymphocytes contribute to this
immunosuppressed state(2, 3, 13). Secondary lymphoid organs taken from septic patients
have lower cellular density compared to healthy controls, with loss of antigen-presenting cells 
and T cell exhaustion that may impair B cell maturation(3, 13, 14). Murine sepsis models
identify early B cell activation by type-1 interferon yet despite depletion of the naïve mantle 
zone B cell compartment, peripheral B cell maturation progresses unhindered(15). B cells 
have both antibody-dependent and independent functions in such sepsis models. For 
example, impaired cytokine production and reduced survival in recombination-activating 
gene deficient (RAG1-/-) septic mice could be replicated in wild-type models after depletion of 
B cells using anti-CD20 antibodies. Survival rates increased in these RAG1-/- mice when 
treated with either serum or with B cells from wild-type mice(15). In other models using
chimeric and knockout mice, a novel B cell effector subset was identified that secretes 
granulocyte-monocyte colony stimulating factor, reduces illness severity by altering cytokine 
profiles, enhances pathogen clearance and improves sepsis outcomes(16). 
Current knowledge of human B cells in sepsis is sparse, discordant, and at variance 
with findings reported from animal models. Descriptions of sepsis related abnormalities in the 
B cell compartment are limited to inconsistent reports of changes in absolute counts, in 
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activation status(17-20), and immunoglobulin levels(21). Optimal management of patients 
with sepsis requires a clear understanding of the potential for manipulation of the humoral 
response and how the B cell compartment could support healthy life after recovery. We 
tested the hypothesis that B cell loss in sepsis involves distinct sub-populations of B cells and 
investigated the mechanisms of B cell depletion. 
MATERIALD AND METHODS
Study design and setting
This prospective observational cohort study was performed in the general medical-
surgical critical care units of a university hospital.  Ethics Committee approval was obtained 
prior to start of recruitment (10/H0807/81 and 12/LO/0326; Camberwell St Giles Committee, 
England). Clinical management were at the discretion of the attending physicians. Informed 
consent was obtained from patients or, where they lacked competency, from Personal Legal 
Representatives. Retrospective consent was sought from patients after they regained mental 
competency. 
Study population
Consecutive patients with sepsis (previously severe sepsis/septic shock(22)) within 
the first 12 hours following ICU admission between 05/2011 and 01/2015 were included. 
Sepsis was defined as evidence of two or more systemic inflammatory response syndrome 
criteria, with proven or suspected infection and at least one organ system dysfunction 
(cardiovascular, respiratory, renal, hematological or metabolic)(22). Exclusion criteria 
included patients < 18 years, those with congenital hypo-gammaglobulinemia; known protein-
losing enteropathies; nephrotic syndrome; neoplastic or proliferative hematological diseases; 
those having received IVIg therapy in the last 3 months; those receiving high-dose 
corticosteroid therapy; on-going blood loss (defined by blood transfusion requirement > 2 
units/24 hour period); retroviral disease and immune dysfunction as defined by Acute 
Physiology and Chronic Health Evaluation (APACHE) II score co-morbidities(23).
Clinical data and blood sampling 
Baseline demographic data, daily laboratory results, daily worst physiological 
variables, the APACHE II (23) and the Sepsis-related Organ Failure Assessment (SOFA) 
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scores(24) were obtained from the clinical information system (CareVue™, Philips and 
Electronic patient records).  Fresh blood samples for all experiments were collected daily 
from admission day until day-7 following ICU admission, if sooner on the day of demise or 
discharge (defined as final measurement (DF)).
Flowcytometry
For isolating peripheral blood mononuclear cells (PBMCs) and for whole blood flow 
cytometry, EDTA anti-coagulated blood was collected. All anti-human fluorchromes were 
from Becton Dickinson (BD) unless otherwise specified. For each target molecule, the 
fluorochome and clone used are reported in parenthesis. For all experiments, Amcyan 
(L34957; Invitrogen) was used to identify alive cells. To estimate the absolute B cell counts 
in sepsis patients, whole blood (50μL) and beads were labelled for 20 minutes at room 
temperature using CD19 (PE; LT19), CD45 (PeCY7; H130) and CD69 (FITC; FN50) antibody 
combinations and the corresponding isotype controls and estimated using flow-cytometry on 
Canto-A flowcytometer (BD) using Diva Software Version6.1 following RBC lysis. Admission 
day and DF absolute B-cell counts are reported.
For all other experiments, PBMCs were isolated within 4 hours of blood sampling
using Ficoll density centrifugation and stored in liquid nitrogen as viable cells for future 
analysis. To identify B cell subsets, we used: anti-CD19 (PerCP Cy5.5; HB19); anti-CD24 
(PeCYTM7; ML5); anti-CD27 (APC; MT271), anti-CD38 (PE; HIT2; eBioscience); anti-IgM 
(V450; G20-127); anti-IgA (FITC; IS11-8E10; Miltenyi); anti-IgG (APCH7; G18-145); Annexin-
V (PeCYTM7; eBioscience); anti-CD27 (FITC; O323; eBioscience); anti-p-ERK (PE; RateK1); 
anti-p-BTK (ALexafluor674; 24a/BTK); anti-p-SYK (Alexafluor488; human syk peptide); anti-p-
AKT (APC; eBioscience). Staining for phosphorylation status of intracellular kinases was 
performed using the BD Cytofix/Cytoperm kit and phosphoflow buffers as per manufacturer 
guidelines. Flow cytometer set up and calibration was done for every experiment. Regents 
remained the same during the course of the study. Gating during analysis of FCS files were 
achieved using isotype controls, fluorescence minus-one controls and/or single stain controls.
Admission day B-cell subset profiles are reported.
Enzyme linked immunosorbent assay (ELISA)
Quantitative detection of human B cell–activating factor of the tumour necrosis factor 
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family (BAFF) and a proliferation inducing ligand (APRIL) in admission day serum in sepsis 
patients and age-matched healthy controls were done in triplicate using commercial ELISA 
kits from eBioscience.
Microarray
CD19+ B cells from sepsis and healthy controls were isolated to a purity of >99% 
using EasySep® Positive Selection kit (Stem Cell Technologies). Purity was confirmed with
flow cytometry. Total RNA was isolated using the RNeasy Mini Kit (Qiagen).  RNA was 
converted to cDNA using the Ovation® Pico WTA Systems V2 and labelled using the Encore®
BiotinIL Module (Nugen). Labelled cDNA was hybridized onto Infinium Illumina HT12v4 
arrays and data collected on an iSCAN array scanner (Illumina). Following scanning, basic 
QC statistics were completed, displaying hybridisation controls, background signal and mean 
gene intensity of all genes and those of housekeeping genes. Array results were compiled 
using Genome Studio (Illumina) following quantile normalisation. Differences in messenger 
RNA abundance between the sepsis and healthy controls were assessed using Partek 
Genomic Suite (Partek Inc.). Similarities and differences in cell specific gene expression 
pattern in health and sepsis were assessed using heat maps and the top canonical pathways
identified using Ingenuity Pathway Analysis (IPA) (Qiagen). Apoptosis genes and pathways 
were also studied.
Healthy controls
Every experiment had samples from sepsis patients and contemporaneous healthy controls.
Blood was sampled from contemporaneous healthy controls who were consented prior to 
sampling as per the King’s College London Infectious Diseases Biobank protocol (25) and 
used for ELISA assays (n=13), flowcytometry (n=48) and microarrays (n=6) experiments.
The control individuals were age and gender frequency matched to within 5 years of the 
sepsis samples. Aside from mean fluorescent intensity (MFI) comparisons by apoptosis 
status within sepsis, all other comparisons were done between healthy controls and sepsis.
Statistics
Continuous data are presented as mean and standard deviation (SD) when normally 
distributed and as median and interquartile range (IQR) when not. Frequency and 
percentages are presented for categorical data. Statistical tests included unpaired or paired t-
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tests or the corresponding non-parametric equivalents where appropriate accounting for 
unequal variances. All analyses were performed using Prism6. Reported p values are two 
sided with p values <0.05 representing a statistically significant result. 
RESULTS
Study cohort
Mean (SD) age was 64.8 (13.7) years and 62.4% were male. The respiratory tract 
was the most common infection site (64.4%), followed by intra-abdominal (15.0%), wound, 
bone and soft tissue (11.0%), and urinary tract (6.9%). The mean (SD) APACHE II score was 
19.5 (5.7) and the median (IQR) SOFA Score was 7 (6, 9). Acute hospital mortality was 
26.7% (eTable1).
Sepsis patients have a high prevalence of lymphopenia, low absolute B cell counts 
and normal B cell specific survival factor concentrations. 
Lymphopenia was defined as an absolute lymphocyte count <1.2 x 109 cells/L. Persistent and 
more severe lymphopenia was observed in non-survivors compared to survivors over the 
first seven days of ICU stay (p<0.001 on days 2, 3, 4 and 5; comparing absolute lymphocyte 
counts; Figure1a; eFigure1). Sequential investigations were performed to test the study 
hypothesis that used samples from randomly selected sepsis patients and matched controls.  
To permit this range of detailed investigations, all 101 sepsis patient samples were not used 
for all parts of the study reported in this paper.
On admission day, the median (IQR) B cell count was 0.133 (0.093 – 0.277) 109cells/L and 
there was no statistically significant differences in B-cell counts between admission day and 
DF (p=0.23) in sepsis (Figure1b), subsequent experiments were performed using admission 
day samples in sepsis. There were no differences between sepsis patients and healthy 
controls in the serum levels of B cell specific survival factors (BAFF - Figure1c; APRIL - 
Figure1d). 
Sepsis associated B cell depletion is most severe in memory B cell subsets
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B cell subsets were quantified by flow cytometry as the proportion of live CD19 cells 
in PBMCs. The gating strategy is shown in eFigure2. No difference was seen between sepsis 
patients and healthy controls in the frequency of transitional B cell subsets (p=0.70 for T1; 
p=0.21 for T2; Figure2a) and the proportion of naïve B cells (Figure2b).  In marked contrast,
the proportions of plasmablasts, IgM memory B cells and class-switched memory B cells 
were all significantly lower (p=0.002 for plasmablasts; p=0.0002 for IgM memory; p=0.001 for 
IgA memory cells and p=0.013 for IgG memory) (Figure2c-f).
B cell apoptosis in sepsis is highest in memory B cell subsets that have the highest 
relative ERK phosphorylation
B cell apoptosis was assessed by flow cytometry as the proportion of Annexin-V 
status in live-dead stain negative (live) CD19 cells. In each sample, each B cell subset was 
used as its own denominator to estimate the proportion of apoptotic cells within. The gating 
strategy is shown in eFigure3. B cell apoptosis was highest in the memory subsets
(Figure3a), which were also the B cell subsets with greatest proportional depletion (Figures2d-
f).
Phosphorylation of intracellular kinases such as ERK can be considered as
surrogates for intracellular stress signalling(26, 27). In sepsis patients, the p-ERK MFI was 
significantly higher in IgM memory (p=0.0002) and CSR memory (p=0.004) subsets when 
compared to naive B-cells (Figure 3b; left panel). In contrast, this was difference was not 
observed in B-cells from healthy subjects (Figure3b; right panel). In sepsis, annexin-V
positive CD19 B cells had significantly higher p-ERK MFI compared to annexin-V negative 
cells (p=0.002; Figure3c); these differences were replicated in the B cell subsets (Figures 3d-
f). Reciprocal changes were observed in the CD22 MFI, another key BCR signalling 
modulator (28) (Figures4a-d), supporting the hypothesis that B cell death is a non-random 
event associated with an activated profile. No differences between apoptotic and non-
apoptotic B cells were seen in phosphorylation of the more BCR proximal kinases, Bruton’s 
tyrosine kinase (BTK) and spleen tyrosine kinase (SYK) (eFigure4) and in protein kinase B 
phosphorylation (p-AKT) in sepsis compared to health, though memory cells in general had 
more p-AKT than naïve B cells (Figure4e).
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Gene expression profiles of purified B cells also supports activation-induced cell 
death in sepsis
Salient clinical characteristics of the six sepsis patients whose B-cell gene 
expression were studied using microarray are shown in eTable2. Heat maps show clear 
clustering segregating the sepsis and healthy groups (eFigure7a; eTable3). Significant 
alterations in canonical pathways of oxidative phosphorylation (p=0.0007), cyclins and cell 
cycle regulation (p=0.001), mitochondrial dysfunction (p=0.005) and in serine and glycine 
biosynthesis (p=0.005). Comparing B cell apoptosis regulator gene status in sepsis compared 
to health (eFigure6), two B cell apoptosis networks in sepsis involving both mitochondrial and 
death receptor pathways were identified (eFigure8). ERK either influenced (n=15) or was
influenced by (n=14) or had a bidirectional relationship with (n=5) 34 apoptosis regulator
genes in this dataset (eFigure7b), implying a potentially important role for ERK in activation-
associated B cell death in sepsis. A simplified schematic overview of activation associated B 
cell death using the genes identified in the two apoptosis networks is shown in eFigure7c.
DISCUSSION
Changes in the relative proportions of B cell subsets in critically ill patients with 
sepsis are reported here for the first time. B cell depletion is an acute phenomenon as it was 
observed on admission day samples, with an exaggerated proportional loss of antigen-
experienced B cell subsets, i.e. plasmablasts and memory cells. B cell apoptosis is greater in 
memory cells compared to naïve B cells, consistent with the finding that these B cell subsets 
are the most depleted. This suggests that B cell depletion is not a consequence of impaired 
bone marrow production. 
The observed cell death events occurred despite normal concentrations of BAFF and 
APRIL and involve well-characterised, activation-associated apoptosis pathways. In health, 
generation of high affinity antibody responses depends on T cell functionality since it requires 
B cell: T cell cognate interaction for the generation of germinal centre responses (29, 30). 
There are well-characterised abnormalities in T cell effector function in sepsis (3, 31-37) that
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may explain the lower frequencies of memory cells and plasmablasts observed. Our data 
suggest that this depletion is related to a higher susceptibility to death rather than a failure to 
create them due to a lack of T cell help. 
The B-cell receptor (BCR) complex is composed of a cell-surface immunoglobulin 
molecule non-covalently bound to the antigen-nonspecific signalling protein dimer CD79a 
and CD79b. BCRs have two main roles, antigen binding and transmitting signals to regulate 
B cell fate decisions(28). BCR crosslinking activates SRC family kinases such as LYN, which 
phosphorylates the immune tyrosine based activation moieties (ITAM). Binding of SYK to 
these double phosphorylated ITAM moieties activates SYK, which then rapidly 
phosphorylates the scaffold protein B cell linker (BLNK). Phospholipase C-gamma 2 is 
activated secondary to BLNK and BTK interactions, which results in transcription factor 
activation and activation of downstream ERK1/2 kinases via phosphorylation (38). Of the 
three BCR signalling pathway kinases studied, only p-ERK MFI was significantly higher in the 
more apoptotic IgM and CSR memory B cell subsets, when compared to naïve B cells from 
the same subjects, with no evidence for increased phosphorylation of the more BCR 
proximal kinases BTK and SYK. This implies that on ICU admission day, B cells from sepsis
patients are not in the early stages of activation through their BCR. It would be highly unlikely 
that the memory populations with activated profiles would all have antigenic specificity for 
the causal infectious agent(39). 
Phosphorylation of ERK can be associated with transition to an apoptotic state(40-
42). Memory B cell subsets have different susceptibilities to apoptosis when compared to 
naïve B cells (43). Determinants of the four potential fates of activated B cells (division, 
death, differentiation, and class switch), are complex and only predictable with limited 
certainty(44). Data presented here suggest that cell death in sepsis is externally driven 
rather than through the BCR while ERK plays an important role in activation-associated B 
cell death in sepsis. The microarray analyses of the B cells identified mitochondrial 
dysfunction with alterations in ATP5J, ATP50, cytochrome C oxidase subunit 8A, NADH 
dehydrogenase 1 sub complexes alpha-1 and beta-10 genes and the serine/glycine super 
pathways (which included the genes PHGDH and SHMT2)(45, 46). When taken together, 
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these alterations in gene expression also support the concept of activation-associated B cell
death in sepsis (eFigures7a-c).
Immunosuppression is a clinically valuable term used to communicate acute 
impairment of the immune system in sepsis. This persists beyond the acute illness in sepsis 
survivors, with a marked reduction in cellularity in the secondary lymphoid organs(3, 13, 47). 
Reversing this suppression requires a better understanding of contributory factors during the 
acute phase, and of factors that maintain this state thereafter. Current paradigms to reverse
this sepsis related immunosuppression focus on interventions such as anti-interluekin-3, 
interleukin-7, anti programmed death ligand-1 antibody, and granulocyte-monocyte colony 
stimulating factor aimed at managing excess inflammation and/or acute functional 
impairment. Two fundamentally different facets to sepsis immunosuppression should 
perhaps be considered independently: functional (immune dysfunction) and structural 
abnormalities (immune depletion). The latter is particularly relevant when considering 
infection-related re-admissions in sepsis survivors (7-11). We identified that B cell depletion 
preferentially affects memory B cell subsets. This could be due to either impaired secondary 
lymphoid organ maturation and/or accelerated apoptosis in the peripheral circulation. The 
relative contributions of these different mechanisms on B cell subsets require further 
elucidation. Restoring immune capability thus requires replenishment of B cell numbers as 
well as boosting the memory cell pool with antigen challenge to replenish lymphocyte 
cellularity in secondary lymphoid organs of sepsis survivors.   
CONCLUSIONS
We report selective depletion of antigen-experienced B cells in sepsis. Depletion of 
the memory B cell compartment contributes to the immunosuppression induced by sepsis.
Therapies targeted at reversing this immune depletion state should be actively investigated.
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FIGURE LEGENDS
Figure 1 | Sepsis associated B cell depletion occurs with normal survival factor 
concentrations. 
Figure 1a: Dot plot shows lymphopenia is common in both survivors (n=74) and non-
survivors (n=27), with a hospital mortality of 26.3% (eTable-1). Lymphopenia was 
defined as absolute lymphocyte counts (ALC) <1.2x109 cells/L (marked as the 
shaded region under the reference line). Non-survivors have more severe and 
persisting lymphopenia (p<0.01 on days 2, 3, 4, 5 and 6 using t-tests). Patients with 
persistent lymphopenia by day 4 had worse survival at 90 days (eFigure-1). 
Proportions of survivors versus non-survivors with lymphopenia by days of ICU stay 
are shown as italics in the x-axis and were not compared for statistical differences. 
The proportions of patients with severe lymphopenia (ALC<0.6x109cells/L) were also 
more common in non-survivors (D1= 39.1% vs. 59.3% (p=0.03) and D2 = 25.7% vs. 
59.3% (p=0.007); compared using χ2 tests). Figure 1b: Dot plot of admission (D1) 
and final day (DF) absolute B cell count shows significantly lower counts in sepsis 
patients (n=24) on admission day when compared to population median values 
(median reference line=0.233 x 109cells/L). Absolute lymphocyte counts on D1 and 
DF in sepsis patients were 0.133 (0.93 – 0.277) and 0.224 (0.12 – 0.525) x 109
cells/L respectively. Shaded regions represent normal range in healthy adults. The 
admission day and DF absolute B-cell counts were compared to assess whether the
B-cell counts change significantly during the 7-day period. As there were no 
statistically significant differences in B-cell counts between D1 and DF (p=0.23), 
subsequent experiments presented in this paper were done using admission day 
samples. Figure 1c: BAFF concentrations (median (IQR) ng/mL) were similar on 
ICU admission day in sepsis patients (n=62) [0.14 (0.09–0.20)] versus healthy 
controls [0.11 (0.07–0.25]); Figure 1d: APRIL concentrations (median (IQR) ng/mL) 
were similar between on ICU admission day in sepsis (n=26) patients (2.31 
(1.29–8.26) versus healthy controls [2.39 (2.35 – 5.65)] (Mann-Whitney Test). 
Admission day = D1; DF represents either day 7 samples, or last day of ICU stay or 
death.
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Figure 2 | In the context of absolute low B cell counts, the memory B cells and 
plasmablasts are proportionally more depleted in sepsis
The proportions of functional B cell subsets (naïve, transitional, plasmablasts and 
memory B cells) in sepsis were analysed using flowcytometry on PBMCs stained with 
CD19, CD24, CD38, CD27, IgG, IgA, IgM and amcyan. B cell subsets are reported 
as proportion of the live CD19 population.  Proportions were compared between 
matched healthy samples (n=23) and sepsis patients (N=29) for statistically 
significant differences using Mann Whitney tests. Dot plots reporting proportions 
shows all data points alongside median and IQR as summary distribution. The gating 
strategy used to identify B cell subsets shown in eFigure2. Figure 2a: Shows the 
median (IQR) transitional (T1) B cells in healthy individuals and sepsis patients were 
1.04% (.76% - 1.63%) and 1.38% (0.62% - 1.87%) respectively (p=0.70) and T2 B 
cells were 2.37% (1.48% - 3.06%) and 2.95% (1.69% - 4.72%) respectively (p=0.21). 
Figure 2b: Shows the median (IQR) naïve B cells as a proportion of alive CD19 
population in health was 54.9% (45.1% - 66.6%) and in sepsis was 70.9% (56.8% - 
74.7%); p=0.043).  Figure 2c-f: Shows that sepsis patients have a significantly lower 
proportion of potentially antigen experienced cells (Figure 2c: plasmablasts (0.36% 
[0.14% - 0.80%] in sepsis compared to 1.05% [0.49 – 1.64%; in health: p=0.002);
Figure2d: IgM memory (4.0% [2.3-9.5%] in sepsis compared to 9.1% [7.1%-8.2%] in 
health; p=0.0002); Figure2e:IgA memory (2.54% [1.39% - 4.50%] compared to 
5.33% [3.75% - 8.48%] in health; p=0.001) and Figure 2f: IgG memory (4.23% 
[2.38% - 6.47%] in sepsis compared to 6.63% [4.62% - 10.5%] in health; p=0.013).
Figure 3 | B cell apoptosis in sepsis was proportionally higher in memory B-
lymphocyte subsets and associated with higher MFI for phosphorylated ERK1/2 
without concomitant higher MFI for BTK and SYK
Figure 3a: Dot plots showing proportions of apoptosis (Annexin-V staining) in B cell
subsets analysed using flow cytometry. To ascertain statistical differences between 
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matched healthy samples (n=12) and sepsis (n=19), the proportions of Annexin-V 
positive cells within each subset were compared (gating shown in eFigure2). Sepsis 
samples had a significantly higher proportion apoptotic naïve B cells: (2.33% [1.70% - 
4.03%] in sepsis compared to 1.25 [0.51% - 1.68%]; p=0.0002 in health); IgM 
memory (3.85%  [2.50% – 7.04%] in sepsis compared to 1.81% [0.76% - 2.67%]; 
p=0.0002) and class switched memory B cells (8.97% (7.77%-11.57%) in sepsis 
compared to 2.76% (1.92% - 4.52%) in health; p=0.0007) (Figure-3a). The Class 
switched memory B cell subset showed the greatest extent of apoptosis, which also 
was the proportionally most deplete B cell subsets (refer Figure-2). Figure 3b-e: To 
ascertain differences in key regulatory and BCR signalling molecules, after cell
surface with CD19, CD27, CD22, IgM and annexin-V, the cells were fixed and 
permeabilised followed by intracellular staining for phosphokinases and AKT (gating 
shown in eFigure-3). Only paired tests were used to compare the differences within 
sepsis and within health by apoptosis status to account for experimental differences 
in MFI, importantly no statistical comparisons between sepsis versus health were 
conducted. Shows the significant differences observed between apoptosis and non-
apoptosis B cell population for p-ERK status in sepsis patients (n=10) compared to 
health (n=5). There were significant differences between p-AKT, p-BTK and p-SYK 
(eFigure 4) status with these comparisons.
Figure 4 | B cell apoptosis in sepsis was associated with reciprocal lower MFI for 
CD22 without concomitant higher MFI for BTK and SYK
To ascertain differences in key regulatory and BCR signalling molecules, after cell 
surface with CD19, CD27, CD22, IgM and annexin-V, the cells were fixed and 
permeabilised followed by intracellular staining for phosphokinases and AKT (gating 
shown in eFigure-3).  Only paired tests were used to compare the differences within 
sepsis and within health by apoptosis status to account for experimental differences 
in MFI, importantly no statistical comparisons between sepsis versus health were 
conducted. Figure 4a-d shows the significant differences observed between 
apoptosis and non-apoptosis B cell population for CD22 status in health samples 
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(n=7) and sepsis (n=9). There were significant differences between p-AKT, p-BTK 
and p-SYK (eFigure 4) status with these comparisons.
21
Type of file: figure
Label: Figure-1
Filename: Figure-1.tiff
Page 1 of 1
06/02/2017file:///C:/Adlib%20Express/Work/20170206T134614.864/%7B7204BA08-9D...

Type of file: figure
Label: Figure-2
Filename: Figure-2.tiff
Page 1 of 1
06/02/2017file:///C:/Adlib%20Express/Work/20170206T134614.864/%7B2F467659-AE...

Type of file: figure
Label: Figure-3
Filename: Figure-3.tiff
Page 1 of 1
06/02/2017file:///C:/Adlib%20Express/Work/20170206T134614.864/%7B694A9BDA-4...

Type of file: figure
Label: Figure-4
Filename: Figure-4.tiff
Page 1 of 1
06/02/2017file:///C:/Adlib%20Express/Work/20170206T134614.864/%7B25A47B86-EE...

Europe PMC plus has received the file 'ESM.CCMED-D-16-01239.R1.clean.doc' as 
supplementary data. The file will not appear in this PDF Receipt, but it will be linked to the 
web version of your manuscript. 
Page 1 of 1
06/02/2017file:///C:/Adlib%20Express/Work/20170206T134614.864/%7BAABEB73E-1...
